Trisalus Life Sciences Inc (TLSI)

Intrahepatic Cholangiocarcinoma Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key ... - openPR

openPR

Intrahepatic Cholangiocarcinoma Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key ... - openPR

openPR

Intrahepatic Cholangiocarcinoma Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key ... - openPR

openPR

TriSalus Life Sciences: Falling Despite Moving Forward Into The Market (NASDAQ:TLSI) - Seeking Alpha

Seeking Alpha

Comparing TriSalus Life Sciences (NASDAQ:TLSI) and Utah Medical Products (NASDAQ:UTMD) - Defense World

Defense World

TriSalus Life Sciences looks for incentives to grow in Westminster – BizWest - BizWest

BizWest

TriSalus Life Sciences looks for incentives to grow in Westminster – BizWest - BizWest

BizWest

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 140.2% in May - MarketBeat

MarketBeat

Clear Street LLC Invests $60000 in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) - Defense World

Defense World

Clear Street LLC Invests $60000 in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) - Defense World

Defense World

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via ... - Business Wire

Business Wire

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via ... - Yahoo Finance

Yahoo Finance

TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World

Defense World

TriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Analysts at Canaccord Genuity Group - MarketBeat

MarketBeat

Canaccord Genuity upbeat on TriSalus stock, cites innovative oncology treatments By Investing.com - Investing.com

Investing.com

Canaccord Genuity upbeat on TriSalus stock, cites innovative oncology treatments - Investing.com India

Investing.com India

Canaccord Genuity upbeat on TriSalus stock, cites innovative oncology treatments By Investing.com - Investing.com

Investing.com

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Short Interest Update - Defense World

Defense World

TriSalus Life Sciences Inc (TLSI) Stock: A Comprehensive 52-Week Review - The InvestChronicle

The InvestChronicle

Analysts' Revisions Show Improving Sentiment For TriSalus Life Sciences Inc (NASDAQ: TLSI) – Stocks Register - Stocks Register

Stocks Register

Investor's Toolkit: Key Ratios for Assessing TriSalus Life Sciences Inc (TLSI)'s Performance – DWinneX - The Dwinnex

The Dwinnex

TriSalus Life Sciences launches exchange offer for warrants By Investing.com - Investing.com

Investing.com

TriSalus Life Sciences launches exchange offer for warrants - Investing.com South Africa

Investing.com South Africa

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants - Business Wire

Business Wire

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants - Business Wire

Business Wire

Fractyl Health (NASDAQ:GUTS) versus TriSalus Life Sciences (NASDAQ:TLSI) Head-To-Head Review - Defense World

Defense World

Navigating the Financial Tightrope: Trisalus Life Sciences' High-Stakes Debt Strategy with OrbiMed - TipRanks.com - TipRanks

TipRanks

TriSalus Life Sciences, Inc. (TLSI) Q1 2024 Earnings Call Transcript - Seeking Alpha

Seeking Alpha

TriSalus Reports Q1 2024 Financial Results and Business Update - Manchestertimes

Manchestertimes

TriSalus Reports Q1 2024 Financial Results and Business Update - Business Wire

Business Wire

TriSalus Reports Q1 2024 Financial Results and Business Update - Business Wire

Business Wire

TriSalus Life Sciences (NASDAQ:TLSI) Research Coverage Started at Jonestrading - Defense World

Defense World

TriSalus shares gain as Jones Trading sets price target - Investing.com

Investing.com

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Down 38.6% in April - MarketBeat

MarketBeat

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Down 38.6% in April - MarketBeat

MarketBeat

TriSalus shares gain as Jones Trading sets price target By Investing.com - Investing.com

Investing.com

TriSalus Life Sciences appoints new board member By Investing.com - Investing.com Australia

Investing.com Australia

Uveal Melanoma Market Is Expected to Showcase a Significant Growth During the Forecast Period - openPR

openPR

TriSalus Life Sciences Expands Board, Welcomes Liselotte Hyveled - TipRanks.com - TipRanks

TipRanks

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors - Business Wire

Business Wire

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors - Business Wire

Business Wire

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call - Winchester Herald Chronicle

Winchester Herald Chronicle

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call - Business Wire

Business Wire

InspireMD (NYSE:NSPR) vs. TriSalus Life Sciences (NASDAQ:TLSI) Head to Head Comparison - Defense World

Defense World

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call - Business Wire

Business Wire

Analyzing TriSalus Life Sciences (NASDAQ:TLSI) & Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) - Defense World

Defense World

TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System ... - Manchestertimes

Manchestertimes

TriSalus Life Sciences Secures $50 Million Loan Facility - TipRanks.com - TipRanks

TipRanks

TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System ... - Business Wire

Business Wire

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2023 Earnings Call Transcript - Yahoo Finance

Yahoo Finance